Sunshine Biopharma (SBFM) EBITDA (2011 - 2026)

Sunshine Biopharma (SBFM) has reported EBITDA for 15 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 18.63% year-over-year to -$1.6 million; the trailing twelve-month figure through Jun 2026 stood at -$5.8 million (up 7.27% YoY), and the FY2025 full-year result was -$6.1 million, down 6.8% from the prior year.
• EBITDA fell to -$1.6 million in Q2 2026 per SBFM's latest filing, from -$1.4 million in the prior quarter.
• Across five years, EBITDA topped out at -$693509.0 in Q2 2022 and bottomed at -$23.3 million in Q4 2022.
• Historically, EBITDA has averaged -$2.6 million across 5 years, with a median of -$1.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: EBITDA plunged 8346.16% in 2022, then jumped 94.93% in 2023.
• Over 5 years, EBITDA stood at -$23.3 million in 2022, then surged by 94.93% to -$1.2 million in 2023, then sank by 73.18% to -$2.0 million in 2024, then increased by 9.88% to -$1.8 million in 2025, then gained by 12.67% to -$1.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$1.6 million, -$1.4 million, and -$1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.